BR0308857A - Composições farmacêuticas contendo promedicamentos de propofol, solúveis em água, e métodos de administrar os mesmos - Google Patents

Composições farmacêuticas contendo promedicamentos de propofol, solúveis em água, e métodos de administrar os mesmos

Info

Publication number
BR0308857A
BR0308857A BR0308857-0A BR0308857A BR0308857A BR 0308857 A BR0308857 A BR 0308857A BR 0308857 A BR0308857 A BR 0308857A BR 0308857 A BR0308857 A BR 0308857A
Authority
BR
Brazil
Prior art keywords
methods
pharmaceutical compositions
compositions containing
soluble
administering
Prior art date
Application number
BR0308857-0A
Other languages
English (en)
Inventor
Peggy Wingard
Eric S Burak
Ekaterina Gibianski
James J Vornov
Original Assignee
Guilford Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29254399&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0308857(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Guilford Pharm Inc filed Critical Guilford Pharm Inc
Publication of BR0308857A publication Critical patent/BR0308857A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Abstract

"COMPOSIçõES FARMACêUTICAS CONTENDO PROMEDICAMENTOS DE PROPOFOL, SOLúVEIS EM áGUA, E MéTODOS DE ADMINISTRAR OS MESMOS". A presente invenção é dirigida a composições farmacêuticas que contêm promedicamentos de propofol solúveis em água e a métodos de administração do promedicamento. Em um aspecto, um método de induzir e/ou manter um estado anestésico generalizado compreende a administração por infusão parenteral de um promedicamento de propofol em uma quantidade suficiente para calisar e/ou manter perda de consciência. Em outro aspecto, um promedicamento de propofol é administrado para produzir um estado sedado em um indivíduo.
BR0308857-0A 2002-04-08 2003-04-08 Composições farmacêuticas contendo promedicamentos de propofol, solúveis em água, e métodos de administrar os mesmos BR0308857A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37024502P 2002-04-08 2002-04-08
US37021302P 2002-04-08 2002-04-08
PCT/US2003/010540 WO2003086413A1 (en) 2002-04-08 2003-04-08 Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same

Publications (1)

Publication Number Publication Date
BR0308857A true BR0308857A (pt) 2005-01-04

Family

ID=29254399

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308857-0A BR0308857A (pt) 2002-04-08 2003-04-08 Composições farmacêuticas contendo promedicamentos de propofol, solúveis em água, e métodos de administrar os mesmos

Country Status (17)

Country Link
US (1) US20050203068A1 (pt)
EP (2) EP1492544A4 (pt)
JP (2) JP5188003B2 (pt)
KR (2) KR20040095352A (pt)
CN (1) CN1649597A (pt)
AU (2) AU2003224851B2 (pt)
BR (1) BR0308857A (pt)
CA (1) CA2480881C (pt)
HU (1) HUP0600241A2 (pt)
IL (2) IL164217A0 (pt)
MX (1) MXPA04009703A (pt)
NO (1) NO20044152L (pt)
NZ (1) NZ535484A (pt)
PL (1) PL373850A1 (pt)
RU (1) RU2297216C2 (pt)
WO (1) WO2003086413A1 (pt)
ZA (1) ZA200407804B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4744149B2 (ja) 2002-12-03 2011-08-10 ファーマサイクリックス インコーポレイテッド 第ｖｉｉａ因子阻害剤としての２−（２−ヒドロキシビフェニル−３−イル）−１ｈ−ベンゾイミダゾール−５−カルボキサミジン誘導体
US8729117B2 (en) 2004-06-02 2014-05-20 Pharmacyclics, Inc. Factor VIIa inhibitor
EP1791521A4 (en) * 2004-09-17 2009-10-21 Eisai Corp North America METHODS OF ADMINISTERING PROPOFOL PROMOTERS WITH WATER SOLUBLE
US20090221532A1 (en) * 2005-07-12 2009-09-03 Mgi Gp, Inc. Methods Of Dosing Propofol Prodrugs For Inducing Mild To Moderate Levels Of Sedation
WO2007131070A2 (en) * 2006-05-04 2007-11-15 Xenoport, Inc. Compositions, dosage forms and methods of treating emesis
KR100755872B1 (ko) * 2006-10-02 2007-09-05 충남대학교산학협력단 미다졸람을 함유하는 염증 예방 및 치료용 약제학적 조성물
JP2010505826A (ja) * 2006-10-05 2010-02-25 エーザイ インコーポレイテッド プロポフォールの水溶性プロドラッグの水ベースの薬学的製剤
WO2008052044A2 (en) * 2006-10-26 2008-05-02 Xenoport, Inc. Use of derivatives of propofol for treating diseases associated with oxidative stress
MX2009012125A (es) 2007-05-09 2010-02-18 Pharmacofore Inc Compuestos terapeuticos.
CN101715437B (zh) 2007-05-09 2013-06-12 特色疗法股份有限公司 立体异构异丙酚治疗性化合物
US20090005444A1 (en) * 2007-06-21 2009-01-01 Xenoport, Inc. Use of propofol prodrugs for treating alcohol withdrawal, central pain, anxiety or pruritus
US20090076141A1 (en) * 2007-09-14 2009-03-19 Xenoport, Inc. Use of Propofol Prodrugs for Treating Neuropathic Pain
JP5733744B2 (ja) * 2007-10-16 2015-06-10 ファーマサイクリックス，インク． 凝血因子ＶＩＩａモジュレーターの製造、組成物及び使用
UY34072A (es) 2011-05-17 2013-01-03 Novartis Ag Derivados sustituidos de indol
CN102397246A (zh) * 2011-11-18 2012-04-04 陕西合成药业有限公司 一种注射用磷丙泊酚钠及其制备方法和用途
CN103172658B (zh) * 2011-12-26 2016-01-20 宜昌人福药业有限责任公司 一种适合药用的前体药物晶型、制备方法及药用组合物
CN102552291A (zh) * 2012-01-04 2012-07-11 陕西合成药业有限公司 一种磷丙泊酚钠静脉给药制剂及其制备方法和用途
RU2535001C1 (ru) * 2013-07-11 2014-12-10 Общество с ограниченной ответственностью "ВИК-здоровье животных" Микроколлоидный раствор пропофола для анестезии
TW201718495A (zh) * 2015-07-28 2017-06-01 貝塔貓製藥股份有限公司 蒽-9, 10-二酮二肟化合物前驅藥及其用途
US9585867B2 (en) * 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
US11478490B1 (en) 2021-03-30 2022-10-25 Epalex Corporation Fospropofol formulations
US11547714B2 (en) 2020-02-05 2023-01-10 Epalex Corporation Fospropofol salts, methods and compositions
US11439653B1 (en) 2021-03-30 2022-09-13 Epalex Corporation Fospropofol formulations
US11628178B2 (en) 2019-03-26 2023-04-18 Epalex Corporation Fospropofol methods and compositions
CN111135304A (zh) * 2020-01-19 2020-05-12 李启芳 治疗慢性、顽固性或原发性失眠症的联合用药物及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2829151A (en) * 1952-11-03 1958-04-01 Dow Chemical Co Chlorotoloxy-ethyl phosphates
US3271314A (en) * 1958-12-04 1966-09-06 Ethyl Corp 2, 6-diisopropylphenol
GB1146173A (en) * 1966-06-18 1969-03-19 Geigy Uk Ltd Production of triaryl phosphates
US3723578A (en) * 1970-10-13 1973-03-27 Gaf Corp Phosphate esters of ethers of thiol substituted phenols
US4171272A (en) * 1977-12-02 1979-10-16 Fmc Corporation Turbine lubricant
FR2601259B1 (fr) * 1986-07-11 1990-06-22 Rhone Poulenc Chimie Nouvelles compositions tensio-actives a base d'esters phosphoriques leur procede de preparation et leur application a la formulation de matieres actives.
MY103951A (en) * 1988-01-12 1993-10-30 Kao Corp Detergent composition
FR2638168A1 (fr) * 1988-10-21 1990-04-27 Rhone Poulenc Chimie Dispersions d'halogenures de terres rares en milieu huileux
DE3900941A1 (de) * 1989-01-14 1990-07-19 Henkel Kgaa Verfahren zur flotation von fuellstoffen aus altpapieren in gegenwart organischer phosphorsaeureester
CA2014539C (en) * 1989-04-17 2000-07-25 Shinichiro Umeda Water borne metallic coating composition
US5091211A (en) * 1989-08-17 1992-02-25 Lord Corporation Coating method utilizing phosphoric acid esters
US5110503A (en) * 1990-05-15 1992-05-05 Elliot Cohen Demulsifying
AU660918B2 (en) * 1990-10-17 1995-07-13 Arysta Lifescience Corporation Method and composition for enhancing uptake and transport of bioactive agents in plants
US5646176A (en) * 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
US5731356A (en) * 1994-03-22 1998-03-24 Zeneca Limited Pharmaceutical compositions of propofol and edetate
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
IT1270093B (it) * 1994-09-28 1997-04-28 Zambon Spa Processo per la purificazione di 2,6-diisopropilfenolo
US5804682A (en) * 1995-11-29 1998-09-08 Henkel Corporation Aqueous dispersions of polyamides
US5637625A (en) * 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations
US5723538A (en) * 1996-06-14 1998-03-03 Henkel Corporation Aqueous dispersions of polyamides
US5746973A (en) * 1996-07-10 1998-05-05 Naraghi; Ali Method for reducing odorant depletion
AU750040B2 (en) * 1998-02-10 2002-07-11 Sicor Inc. Propofol composition containing sulfite
AR015744A1 (es) * 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
US6254853B1 (en) * 1998-05-08 2001-07-03 Vyrex Corporation Water soluble pro-drugs of propofol
MXPA00011835A (es) * 1998-06-03 2002-10-17 Scott Lab Inc Aparato y metodo para proveer alivio del dolor de un paciente consciente y ansiedad asociada con procedimientos medicos o quirurgicos.
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
IL141095A0 (en) * 1998-08-19 2002-02-10 Rtp Pharma Inc Injectable aqueous dispersions of propofol
US7060290B1 (en) * 1999-02-18 2006-06-13 Supergen, Inc. Phosphocholine linked prodrug derivatives
AU3898700A (en) * 1999-03-15 2000-10-04 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
GB2359747B (en) * 2000-02-29 2002-04-24 Maelor Pharmaceuticals Ltd Anaesthetic formulations
SE0001865D0 (sv) * 2000-05-19 2000-05-19 Astrazeneca Ab Management of septic shock
JP2003535884A (ja) * 2000-06-16 2003-12-02 スカイファーマ・カナダ・インコーポレーテッド プロポフォールの改善された注射可能な分散物
US6362234B1 (en) * 2000-08-15 2002-03-26 Vyrex Corporation Water-soluble prodrugs of propofol for treatment of migrane

Also Published As

Publication number Publication date
JP2010195803A (ja) 2010-09-09
AU2003224851A1 (en) 2003-10-27
CA2480881C (en) 2012-09-11
JP5188003B2 (ja) 2013-04-24
EP1492544A1 (en) 2005-01-05
NO20044152L (no) 2005-01-07
JP2005526108A (ja) 2005-09-02
AU2008202880A1 (en) 2008-07-24
IL164217A0 (en) 2005-12-18
CA2480881A1 (en) 2003-10-23
WO2003086413A1 (en) 2003-10-23
US20050203068A1 (en) 2005-09-15
EP2281565A3 (en) 2011-10-26
EP1492544A4 (en) 2005-10-12
NZ535484A (en) 2009-01-31
ZA200407804B (en) 2005-11-30
PL373850A1 (en) 2005-09-19
RU2297216C2 (ru) 2007-04-20
EP2281565A2 (en) 2011-02-09
RU2004129339A (ru) 2005-05-27
CN1649597A (zh) 2005-08-03
HUP0600241A2 (en) 2006-07-28
KR20070087004A (ko) 2007-08-27
IL164217A (en) 2013-02-28
MXPA04009703A (es) 2004-12-13
AU2003224851B2 (en) 2008-04-03
KR20040095352A (ko) 2004-11-12

Similar Documents

Publication Publication Date Title
BR0308857A (pt) Composições farmacêuticas contendo promedicamentos de propofol, solúveis em água, e métodos de administrar os mesmos
BRPI0108380A8 (pt) fórmulas de opióides agonistas resistentes à adulteração, método para diminuir o abuso de um opióide agonista numa fórmula de dosagem oral, método de preparação de uma fórmula de dosagem oral e método de tratamento da dor
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
AR109590A2 (es) Régimen posológico para inhibidores de comt
BRPI0507544A (pt) combinação de agonistas de benzotiazol-2-ona beta-2 adrenoreceptores e corticosteróides para o tratamento de doenças respiratórias
AR025444A1 (es) Derivados de sulfonil-carboxamida, procedimientos para su preparacion y su utilizacion como medicamentos
SE0202857D0 (sv) Method and compositions for preventing hormone induced adverse effects
BRPI0418029B8 (pt) formulação farmacêutica líquida, estável, adequada para administração parentérica que compreende um anticorpo agonista de cd40
BRPI0716439B8 (pt) sistemas de liberação farmacêutico compreendendo flibanserina, processo para preparação e uso dos mesmos
BRPI0407485A (pt) utilização de anticorpos anti-receptores de factor crescimento i semelhantes aos anti-insulina
BR0316685A (pt) Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade
BRPI0518266A2 (pt) medicamento oral de libertaÇço modificada de pelo menos um princÍpio ativo sob a forma multimicrocapsular
BR0011823A (pt) Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo
BR0314943A (pt) Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
DE602005020796D1 (de) Geschmacksabdeckende formulierung mit einer retardierten wirkstoffformulierung und/oder schnell löslichem cyclodextrin
BR0213425A (pt) Composições injetáveis para a liberação controlada de composto farmacologicamente ativo
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
MX2007006637A (es) Uso de atazanavir para mejorar los parametros farmacocineticos de farmacos metabolizados por isoforma 1a1 de udp-glucuronosil- transferasa.
ATE513562T1 (de) Nicht-spezifische immunstimulierende mittel
BRPI0411451A (pt) formas de dosagens orais de memantina
UY27757A1 (es) Medicamento que contiene betamiméticos y un nuevo anticolinérgico.
AR057904A1 (es) Medicamentos que comprenden un agente antimuscerinico y un corticoesteroide
AR030039A1 (es) Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento
KR970025615A (ko) 암 전이 억제제
Kaka et al. Serum concentration of ketamine and antinociceptive effects of ketamine and ketamine-lidocaine infusions in conscious dogs

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MGI GP INC. (US)

Free format text: ALTERADO DE: GUILFORD PHARMACEUTICALS INC.

B25G Requested change of headquarter approved

Owner name: MGI GP INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020060149192/RJ DE 27/09/2006.

B25A Requested transfer of rights approved

Owner name: EISAI CORPORATION OF NORTH AMERICA (US)

Free format text: TRANSFERIDO DE: MGI GP, INC.

B25A Requested transfer of rights approved

Owner name: EISAI INC. (US)

Free format text: TRANSFERIDO DE: EISAI CORPORATION OF NORTH AMERICA

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA.INT.CI. A61K 31/66, A61P 23/00, A61P 25/20

Ipc: A61K 31/66 (2011.01), A61P 23/00 (2011.01), A61P 2

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2307 DE 24/03/2015.